La présente invention a pour objet des composés de formule (I) leurs procédés de préparation ainsi que leurs applications dans le domaine thérapeutique et dans le domaine des matériaux.

The invention relates to the dyeing of keratin fibres using azomethine direct dyes or reduced precursors of azomethine direct dyes of formula (I) and (II) obtained from 2 -amino- 3-hydroxypyridine. The invention relates to a dye composition comprising at least one azomethine direct dye or a reduced precursor of an azomethine direct dye, to a process for dyeing keratin fibres, using the said composition, and to their uses in the dyeing of keratin fibres. This composition allows a particularly stable and fast coloration to be obtained.

The present invention discloses anti-TNF-a activities of compounds in the 5-methyl-1-(substituted phenyl)-2(1H)-pyridone family. An representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3'-fluorophenyl)-5-methyl-2(1H)-pyridone, AKF-PD. Accordingly, there is provided a method of using one or more 5-methyl-1-(substituted phenyl)-2(1H)-pyridones to treat TNF-a mediated diseases such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (Crohn's).

The present invention provides glucosinolate and isothiocyante compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents.

Objects of the present invention are new mono-acylated o-phenylendiamines derivatives of formula (A) wherein Ar is thiophen-2,5-diyl, pyridine-2,5-diyl, pyridine-5,2-diyl, pyridine-2,6-diyl, pyridine-2,4-diyl or 1,4-phenylene, R¹, R² independently from each other represent hydrogen, C_1-12-alkyl, C_2-12-alkenyl, C_2-12-alkynyl, C_3-12-cycloalkyl, the alkyl, alkenyl, alkynyl and cycloalkyl groups being optionally mono or multiple substituted by hydroxy, halogen, C_3-12-cycloalkyl, alkoxy, alkylsulfanyl, acyloxy, alkoxycarbonyl, acyl, C_1-6-alkyl-NH-C(O)-, C_1-6-alkyl-C(O)NH- or -NR³R⁴, or alternatively R¹ is hydrogen, and R² is hydroxyl, alkoxy, C_2-C₁₂-alkenyloxy or phenoxy, which phenoxy group is optionally substituted with methyl, methoxy, halogen, nitro, cyano, trifluoromethyl, ethenyl or -C(O)-O-CH₃, provided that if R² is hydroxy, Ar is not thiophen-2,5-diyl; and R³ and R⁴ independently from each other represent hydrogen or C₁-₆-alkyl, or wherein R³ and R⁴ together with the nitrogen-atom to which they are attached form a ring, which ring is monosubstituted by oxo and which ring may contain a further heteroatom, and pharmaceutically acceptable salts thereof, as well as processes for the manufacturing of these compounds, pharmaceutical compositions containing such compounds and their use in the manufacture of drugs for the treatment of diseases such as cancer.